A Double Switch for the S&P Top Ten

Homebuilder Lennar and generic drugmaker Barr Labs join S&P's portfolio of best investment ideas

On Oct. 24, Standard & Poor's equity research group made changes to the S&P Top 10 portfolio -- those issues it considers to be the best candidates for capital gains over the next 6 to 12 months. S&P replaced Intrado (TRDO ; recent price, $16.50) and Compass Bancshares (CBSS ; $37) with Barr Laboratories (BRL ; $74) and Lennar (LEN ; $85).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.